Valuation : OliX Pharmaceuticals, Inc

Market Cap 2,222B 1.62B 1.4B 1.31B 1.2B 2.25B 154B 2.26B 15.54B 6.05B 78.2B 6.08B 5.95B 259B P/E 2026 *
-68.2x
P/E 2027 * -70.1x
Enterprise Value 2,222B 1.62B 1.4B 1.31B 1.2B 2.25B 154B 2.26B 15.54B 6.05B 78.2B 6.08B 5.95B 259B EV / Sales 2026 *
278x
EV / Sales 2027 * 202x
Free-Float
83.34%
Yield 2026 *
-
Yield 2027 * -
14/08 OliX Pharmaceuticals, Inc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
30/07 OliX Pharmaceuticals, Inc Reports Preclinical Data Demonstrating Greater Visceral Fat Reduction with Olx501a Versus Global Comparator in Obese Non-Human Primates CI
08/07 OliX Pharmaceuticals, Inc announced that it has received KRW 10.526832833 billion in funding from Business Opportunities for L'Oréal Development CI
29/06 OliX Pharmaceuticals, Inc announced that it expects to receive KRW 10.526832833 billion in funding from Business Opportunities for L'Oréal Development CI
05/06 OliX Pharmaceuticals, Inc announced that it has received KRW 110.758162833 billion in funding from Business Opportunities for L'Oréal Development, Weiss Asset Management LP CI
01/06 OliX Pharmaceuticals, Inc announced that it expects to receive KRW 110.758162833 billion in funding from Business Opportunities for L'Oréal Development, Weiss Asset Management LP CI
15/05 OliX Pharmaceuticals, Inc Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
01/04 Ollix Receives Patent Registration Decision from the United States Patent and Trademark Office CI
16/03 OliX Pharmaceuticals, Inc Reports Earnings Results for the Full Year Ended December 31, 2025 CI
08/02 Vect-Horus Reports CNS-Focused Research Collaboration with OliX Pharmaceuticals CI
02/12 Olix Pharmaceuticals receives milestone payment from L'Oréal RE
14/11 OliX Pharmaceuticals, Inc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
28/08/25 OliX Pharmaceuticals, Inc announced that it has received KRW 115.002040047 billion in funding from a group of investors CI
1 day+2.03%
1 week+5.08%
Current month+2.03%
1 month+11.29%
3 months-38.95%
6 months-41.39%
Current year-24.86%
1 week 96,300
Extreme 96300
108,900
1 month 91,300
Extreme 91300
141,400
Current year 86,600
Extreme 86600
217,000
1 year 75,200
Extreme 75200
217,000
3 years 8,280
Extreme 8280
217,000
5 years 8,280
Extreme 8280
217,000
10 years 8,280
Extreme 8280
217,000
Manager TitleAgeSince
Chief Executive Officer 54 01/02/2010
Director of Finance/CFO 40 -
Corporate Officer/Principal 51 28/03/2022
Director TitleAgeSince
Director/Board Member 61 19/03/2019
Director/Board Member 55 19/03/2019
Chairman 54 01/02/2010
Date Insider Type Main position Quantity % Market Cap. Importance
28/2/25 Exercice

Director

30,000 0.1625%
28/2/25 Exercice

Chief Technology Officer

8,000 0.0433%
Change 5-day change 1-year change 3-year change Capi.($)
+2.03%+5.08%+79.42%+489.39% 1.62B
-0.25%-4.10%+38.38%+92.61% 68.21B
+1.21%+0.80%+46.29%+85.32% 64.25B
-0.25%-1.92%-10.72%+436.70% 26.54B
+0.33%-10.61%+1.95%-16.27% 25.61B
+1.18%-2.23%+30.87%-19.04% 19.88B
-6.09%-12.08%+226.11%+375.00% 17.13B
+0.16%-5.74%-1.60%+531.81% 14.93B
+4.12%+0.30%+52.03%+150.18% 14.1B
-0.24%+5.18%+23.04%+190.97% 12.45B
Average +0.22%-2.91%+48.58%+231.67% 26.47B
Weighted average by Cap. +0.16%-3.17%+41.44%+159.58%

Financials

2026 *2027 *
Net sales 8B 5.83M 5.03M 4.73M 4.31M 8.11M 553M 8.15M 55.94M 21.77M 282M 21.89M 21.42M 934M 11B 8.02M 6.92M 6.51M 5.93M 11.15M 761M 11.21M 76.92M 29.94M 387M 30.11M 29.45M 1.28B
Net income -31B -22.6M -19.49M -18.34M -16.7M -31.41M -2.14B -31.58M -217M -84.37M -1.09B -84.84M -83M -3.62B -30B -21.87M -18.86M -17.74M -16.17M -30.4M -2.08B -30.56M -210M -81.65M -1.06B -82.11M -80.32M -3.5B
Net Debt - -
Logo OliX Pharmaceuticals, Inc
OliX Pharmaceuticals, Inc. is a Korea-based company principally engaged in the research and development of new drugs for intractable diseases based on ribonucleic acid interference (RNAi) platform technologies. The Company’s product profile consists of OLX101, OLX102, OLX103, OLX104, OLX201, OLX301, OLX401 and others. These products are used for the treatment of hypertrophic scars and keloids, atopic dermatitis, androgenic alopecia, diabetic ulcer, age-related macular degeneration (AMD), idiopathic pulmonary fibrosis, neuropathic pain, liver fibrosis. In addition, these products are applied for skin brightening, anti-wrinkle and others. The Company operates its business within domestic market and to overseas markets.
Employees
-
Date Price Change Volume
01/09/26 KRW 105,500.00 +2.03% 190,408
31/08/26 KRW 103,400.00 -2.36% 259,491
28/08/26 KRW 105,900.00 +1.05% 99,942
27/08/26 KRW 104,800.00 +5.54% 219,359
26/08/26 KRW 99,300.00 -1.10% 145,062
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. A226950 Stock